ArticleProceedings of the National Academy of Sciences of the United States of America1985
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1985. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 339 citations in OpenAlex.
- Deciphering bone marrow engraftment after allogeneic stem cell transplantation in humans using single-cell analyses.The Journal of clinical investigation · 2024Trial
- Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia.Annals of hematology · 1993Trial
- Immunomodulation therapy for severe aplastic anemia--ALG versus ALG plus cyclosporin A.The Korean journal of internal medicine · 1989Trial
- Adenosine deaminase type 2 deficiency: From rare to common.Journal of human immunity · 2026Review
- Ropeginterferon alfa-2b as a promising alternative to conventional interferon in CDA type 1: a case report of two siblings.Clinical and experimental medicine · 2025Article
- Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapy.Nature communications · 2025Article
- Interleukin-12 sustained release system promotes hematopoietic recovery after radiation injury.MedComm · 2024Article
- Mendelian randomization of circulating proteome identifies IFN-γ as a druggable target in aplastic anemia.Annals of hematology · 2024Article
- Resolvin E1 improves efferocytosis and rescues severe aplastic anemia in mice.Cell death & disease · 2024Article
- Review
- Resolvin E1 improves efferocytosis and rescues severe aplastic anemia in mice.bioRxiv : the preprint server for biology · 2023Article
- Management of Complex Infections in Hemophagocytic Lymphohistiocytosis in Adults.Microorganisms · 2023Review
- Bone marrow expression of CD68/CD163 macrophages, IL-17 and FOXP3 cells in aplastic anemia and their relation to prognosis.European journal of haematology · 2023Article
- Mechanisms involved in hematopoietic stem cell aging.Cellular and molecular life sciences : CMLS · 2022Review
- Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2).Seminars in immunopathology · 2022Review
- JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia.Med (New York, N.Y.) · 2022Article
- Article
- Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories.The Journal of experimental medicine · 2020Article
- A Review of Clinical and Preclinical Studies on Therapeutic Strategies Using Interleukin-12 in Cancer Therapy and the Protective Role of Interleukin-12 in Hematological Recovery in Chemoradiotherapy.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have investigated interferon as a mediator of hematopoietic suppression in bone marrow failure. Interferon production by stimulated peripheral blood mononuclear cells from patients with aplastic anemia was significantly higher than that observed in controls; spontaneous interferon production by these cells was also high for more than half of aplastic anemia patients. Circulating interferon, not detectable in normal individuals, was detected in 10 of 24 patients. Interferon is a potent inhibitor of hematopoietic cell proliferation and, therefore, may be the mediator of suppression in many in vitro models employing patients' cells and sera. The possible pathogenic importance of interferon in aplastic anemia was suggested by an increase in hematopoietic colony formation in vitro after exposure of bone marrow cells to antiinterferon antisera (277 +/- 71% increase for patients compared to 1.6 +/- 1.6% for normal individuals). Interferon levels in the bone marrow sera of aplastic anemia patients were high (mean = 203 international units (IU)/ml, n = 8), even in comparison to circulating levels in the same patients. Normal bone marrow sera also contained measurable interferon but at lower levels (41 IU/ml, n = 16), indicating that interferon may be a normal bone marrow product. High concentration of bone marrow interferon, possibly due to abnormal immunologic activity or a reaction to virus infection of the bone marrow, may mediate hematopoietic suppression in aplastic anemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.